EU accepts filing for monthly Abilify for schizophrenia maintenance
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has formally accepted a marketing authorization application for a once-monthly intramuscular depot formulation of Otsuka Pharmaceutical's atypical antipsychotic Abilify (aripiprazole), in line with expectations of a filing by the end of the year.